Related Experiment Video
Updated: Oct 25, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
DCTN2 inhibited cellular senescence through targeting TRIM21 mediated MST2 ubiquitination and activation in
Yanbo Wang1,2, Yaomei He3, Qin Yu4
1Department of Geriatric Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266000, China.
Rationale:
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, and inducing cellular senescence presents a promising therapeutic approach. However, the mechanisms underlying senescence in HCC pathogenesis remain unclear. This study investigated key genes involved in liver cancer senescence.
Methods:
Bioinformatic analyses of HCC datasets identified senescence-related genes, highlighting dynactin subunit 2 (DCTN2). We investigated DCTN2's biological function and regulatory mechanism, analyzed its association with patient prognosis, evaluated the synergistic effects of vilazodone and sorafenib in vitro and in vivo, and examined tumor protein p53 (TP53) mutation-mediated regulation of DCTN2.
Results:
DCTN2 was identified as a novel HCC senescence-associated gene, whose expression was transcriptionally upregulated by TP53 mutation. DCTN2 knockdown induced cellular senescence, thereby inhibiting HCC cell proliferation, migration, invasion and angiogenesis, whereas its overexpression exerted an opposite oncogenic effect. DCTN2 repressed cellular senescence via interaction with TRIM21, which decreased MST2 K63-linked polyubiquitination and ultimately attenuated the Hippo signaling pathway; DCTN2 overexpression correlated with poor HCC prognosis. Moreover, targeting TRIM21 with vilazodone and sorafenib synergistically induced HCC cellular senescence in vitro and in vivo.
Conclusions:
Our findings revealed that DCTN2 suppresses cellular senescence by inhibiting the Hippo signaling pathway in HCC. Targeting the DCTN2/TRIM21/MST2 axis, along with TP53 mutation regulation, offers new therapeutic insights for HCC treatment.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Replicative Cell Senescence
Inhibition of Cdk Activity
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

